GRIFOLS | GRF - Cash And Equivalent


GRIFOLS reported EUR513M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Amadeus IT EUR 677.2M 298.4M Mar/2026
Amarin USD 143.56M 12.5M Jun/2026
argenx SE USD 4.3B 808.71M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Cie Automotive EUR 486.62M 9.22M Dec/2024
Demant DKK 1.33B 188M Dec/2025
Ence Energia y Celulosa EUR 195M 54.6M Mar/2026
Essilor EUR 3.54B 758M Dec/2025
Ferrovial EUR 3.86B 378M Jun/2026
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Genmab DKK 1.5B 18M Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Inditex EUR 5.28B 675M Dec/2025
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024
Viscofan EUR 79.89M 17.1M Mar/2026